A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies
Latest Information Update: 05 Mar 2021
At a glance
- Drugs Sirolimus (Primary) ; Vorinostat (Primary) ; Hydroxychloroquine
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 02 Jan 2020 Planned End Date changed from 1 Feb 2021 to 1 Dec 2021.
- 02 Jan 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2021.